Oct. 25 at 1:30 PM
$LUCD @oaksapollo
Oaksapollo is lying again but his basic math is also sketchy. I cant be bothered to pick apart the MULTIPLE lies but will let you see how EVEN the BASIC Math is wrong. He said
"A 36% growth rate would put Esoguard test volume at about 19,000 Q4 2026, close to
$37M in revenue. Fully diluted with a revenue multiple of 6 (mean for biotech) you get a share price of around
$4."
Fully diluted TODAY there are 230 Million shares outstanding and LUCD is BROKE Summer 2026 so ANOTHER raise is "IMMINENT" 🤩 But we will ignore that!
So 19,000 EsoGuard tests inQ4 2026 times
$1983 per EsoGuard tests is actually close to
$38 Million in Revenue Multiplied by Revenue Multiple of 6 is 😜 228,000,000 BUT we must DIVIDE by the FULLY DILUTED SHARE COUNT of 230,000,000 (its a little more!!😱😱😱) to gives us a share price of
99 CENTS 😱😱😱. 99 CENTS 😱😱😱. 99 CENTS 😱😱😱. 99 CENTS 😱😱😱. 99 CENTS 😱😱😱. 99 CENTS